Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Intrathecal Baclofen Infusion-Botulinum Toxin Combined Treatment Efficacy in the Management of Spasticity due to Cerebral Palsy

Author(s): Riccardo Marvulli*, Giuseppa Lagioia, Giancarlo Ianieri, Lucrezia Dell'Olio, Alessandra Zonno, Mariagrazia Riccardi, Rosa Bianca Sinisi, Laura Belinda Rizzo, Giacomo Farì, Marisa Megna and Maurizio Ranieri

Volume 23, Issue 7, 2024

Published on: 11 January, 2024

Page: [917 - 926] Pages: 10

DOI: 10.2174/0118715273250973230919121808

Price: $65

Abstract

Background: Cerebral Palsy (CP) is a group of permanent, but not unchanging, disorders of movement and/or posture and motor function, which are due to a non-progressive interference, lesion, or abnormality of the developing/immature brain. One clinical presentation is muscle spasticity, which leads to a significant impact on the individual’s functionality and quality of life. Spasticity treatment is multidisciplinary and includes pharmacological and physical intervention; intrathecal baclofen shows a positive effect in severe spasticity and suboptimal response to oral drugs, while local injection of Botulinum toxin type A (BTXA) improves muscle tone, motion and pain.

Objective: The aim of this study was to evaluate the efficacy of the combined intrathecal baclofen infusion (ITB) - botulinum toxin treatment in the management of spasticity in CP.

Methods: 8 patients with spastic tetraparesis were enrolled. All patients were treated with intrathecal Baclofen; in lower limbs, no spastic symptoms appeared, while marked spasticity was noted in upper limbs. We injected the right and left Biceps Brachial (BB) and Flexor Digitorum Superficialis (FDS) muscles with botulinum toxin type A. All patients underwent Myometric measurement, Ashworth Scale, Numerical Rating Scale, and Visual Analogic Scale evaluation before infiltration (T0), 30 days after injection (T1), 60 days after injection (T2), and 90 days after treatment (T3).

Results: All data demonstrated an improvement in spasticity, pain, quality of life, and self-care during the study, with p < 0.05. No side effects appeared.

Conclusion: This study demonstrated the efficacy and safety of intrathecal baclofen infusion and botulinum toxin combined treatment in the management of spasticity, pain, quality of life, and selfcare in CP patients.

« Previous
Graphical Abstract

[1]
Sadowska M, Sarecka-Hujar B, Kopyta I. Cerebral palsy: Current opinions on definition, epidemiology, risk factors, classification and treatment options. Neuropsychiatr Dis Treat 2020; 16: 1505-18.
[http://dx.doi.org/10.2147/NDT.S235165] [PMID: 32606703]
[2]
Monbaliu E, De La Peña MG, Ortibus E, Molenaers G, Deklerck J, Feys H. Functional outcomes in children and young people with dyskinetic cerebral palsy. Dev Med Child Neurol 2017; 59(6): 634-40.
[http://dx.doi.org/10.1111/dmcn.13406] [PMID: 28272743]
[3]
Blackman JA, Svensson CI, Marchand S. Pathophysiology of chronic pain in cerebral palsy: Implications for pharmacological treatment and research. Dev Med Child Neurol 2018; 60(9): 861-5.
[http://dx.doi.org/10.1111/dmcn.13930] [PMID: 29882358]
[4]
Bax M, Goldstein M, Rosenbaum P. Proposed definition and classification of cerebral palsy. Dev Med Child Neurol 2005; 47(8): 571-6.
[http://dx.doi.org/10.1017/S001216220500112X] [PMID: 16108461]
[5]
Gulati S, Sondhi V. Cerebral palsy: An overview. Indian J Pediatr 2018; 85(11): 1006-16.
[http://dx.doi.org/10.1007/s12098-017-2475-1] [PMID: 29152685]
[6]
Reddihough DS, Collins KJ. The epidemiology and causes of cerebral palsy. Aust J Physiother 2003; 49(1): 7-12.
[http://dx.doi.org/10.1016/S0004-9514(14)60183-5] [PMID: 12600249]
[7]
Hagberg G, Hagberg B, Olow I. The changing panorama of cerebral palsy in Sweden 1954-1970. III. The importance of foetal deprivation of supply. Acta Paediatr 1976; 65(4): 403-8.
[http://dx.doi.org/10.1111/j.1651-2227.1976.tb04906.x] [PMID: 936994]
[8]
Rosenbaum P, Paneth N, Leviton A, et al. A report: The definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109: 8-14.
[PMID: 17370477]
[9]
Palisano RJ, Cameron D, Rosenbaum PL, Walter SD, Russell D. Stability of the gross motor function classification system. Dev Med Child Neurol 2006; 48(6): 424-8.
[http://dx.doi.org/10.1017/S0012162206000934] [PMID: 16700931]
[10]
Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: Incidence, impairments and risk factors. Disabil Rehabil 2006; 28(4): 183-91.
[http://dx.doi.org/10.1080/09638280500158422] [PMID: 16467053]
[11]
Hemachithra C, Meena N, Ramanathan R, Felix AJW. Immediate effect of horse riding simulator on adductor spasticity in children with cerebral palsy: A randomized controlled trial. Physiother Res Int 2020; 25(1): e1809.
[http://dx.doi.org/10.1002/pri.1809] [PMID: 31502387]
[12]
Ayala L, Winter S, Byrne R, et al. Assessments and interventions for spasticity in infants with or at high risk for cerebral palsy: A systematic review. Pediatr Neurol 2021; 118: 72-90.
[http://dx.doi.org/10.1016/j.pediatrneurol.2020.10.014] [PMID: 33563492]
[13]
Bar-On L, Molenaers G, Aertbeliën E, et al. Spasticity and its contribution to hypertonia in cerebral palsy. BioMed Res Int 2015; 2015: 1-10.
[http://dx.doi.org/10.1155/2015/317047] [PMID: 25649546]
[14]
Kumar P, Sankhyan N. Cerebral palsy-more than just spasticity. Indian J Pediatr 2022; 89(4): 321-2.
[http://dx.doi.org/10.1007/s12098-021-04072-1] [PMID: 35041186]
[15]
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol Rev 2017; 69(2): 200-35.
[http://dx.doi.org/10.1124/pr.116.012658] [PMID: 28356439]
[16]
León-Valenzuela A, Palacios JS, Del Pino Algarrada R. IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy - a retrospective case series focusing on dosing and tolerability. BMC Neurol 2020; 20(1): 126.
[http://dx.doi.org/10.1186/s12883-020-01702-7]
[17]
Kim H, Kolaski K. Is botulinum toxin type A more effective and safer than other treatments for the management of lower limb spasticity in children with cerebral palsy? A Cochrane Review summary with commentary. NeuroRehabilitation 2021; 49(1): 161-4.
[http://dx.doi.org/10.3233/NRE-218003] [PMID: 34366300]
[18]
Marvulli R, Chiumarulo P, Nisi M, et al. Use of external intrathecal infusion pumps in the management of septic complications: A case report. Endocr Metab Immune Disord Drug Targets 2015; 15(4): 293-6.
[http://dx.doi.org/10.2174/1871530315666150506124127] [PMID: 25944064]
[19]
William A, George I. Intrathecal baclofen therapy and the treatment of spasticity. Neurosur Quarterly 2007; 17: 185-9.
[20]
Marathe A, Allahabadi S, Abd-Elsayed A, et al. Intrathecal baclofen monotherapy and polyanalgesia for treating chronic pain in patients with severe spasticity. Curr Pain Headache Rep 2021; 25(12): 79.
[http://dx.doi.org/10.1007/s11916-021-00994-9] [PMID: 34894303]
[21]
Balaratnam MS, Stevenson VL. Intrathecal baclofen pumps: What the neurologist needs to know. Pract Neurol 2022; 22(3): 003184.
[http://dx.doi.org/10.1136/practneurol-2021-003184] [PMID: 35314493]
[22]
Schiess MC, Eldabe S, Konrad P, et al. Intrathecal baclofen for severe spasticity: Longitudinal data from the product surveillance registry. Neuromodulation 2020; 23(7): 996-1002.
[http://dx.doi.org/10.1111/ner.13097] [PMID: 31989725]
[23]
Feller CN, Awad AJ, Nelson MES, Ketchum N, Pahapill PA. Low rate of intrathecal baclofen pump catheter-related complications: Long-term study in over 100 adult patients associated with reinforced catheter. Neuromodulation 2021; 24(7): 1176-80.
[http://dx.doi.org/10.1111/ner.13412] [PMID: 33974333]
[24]
Ianieri G, Marvulli R, Gallo G, Fiore P, Megna M. “Appropriate Treatment” and therapeutic window in spasticity treatment with incobotulinumtoxinA: From 100 to 1000 units. Toxins 2018; 10(4): 140.
[http://dx.doi.org/10.3390/toxins10040140] [PMID: 29597251]
[25]
Marvulli R, Ranieri M, Rizzo LB, Marra F, Ianieri G, Megna M. Clinical onset of action of incobotulinum toxin a preparation. CNS Neurol Disord Drug Targets 2022; 22(6): 916-23.
[http://dx.doi.org/10.2174/1871527321666220630154404] [PMID: 35786195]
[26]
Marvulli R, Mastromauro L, Romanelli E, et al. How botulinum toxin type A- Occupational Therapy (OT)-Functional Electrical Stimulation (FES) modify spasticity and functional recovery in patients with upper limb spasticity post stroke. Clin Immunol Endocrine Metabol Drugs 2016; 62-7.
[http://dx.doi.org/10.2174/2212707003666160728143344]
[27]
Ianieri G, Saggini R, Marvulli R, et al. New approach in the assessment of the tone, elasticity and the muscular resistance: Nominal scales vs. MYOTON. Int J Immunopathol Pharmacol 2009; 22(3_suppl): 21-4.
[http://dx.doi.org/10.1177/03946320090220S304] [PMID: 19887038]
[28]
Marvulli R, Megna M, Romanelli E, et al. Effectiveness of the treatment with botulinum toxin Type A (BTX-A) in the management of the spasticity in patients with Amyotrophic Lateral Sclerosis (ALS). Clin Immunol Endocr Metab Drugs 2016; 3(1)
[http://dx.doi.org/10.2174/2212707003666160810143854]
[29]
Munari D, Pedrinolla A, Smania N, et al. High-intensity treadmill training im-proves gait ability, VO2peak and cost of walking in stroke survivors: Preliminary results of a pilot randomized con-trolled trial. Eur J Phys Rehabil Med 2016; 54(3): 408-18.
[PMID: 27575015]
[30]
Picelli A, Bacciga M, Melotti C, et al. Combined effects of robot assisted gait training and botulinum toxin type A on spastic equinus foot in patients with chronic stroke: A pilot, single blind, randomized controlled trial. Eur J Phys Rehabil Med 2016; 52(6): 759-66.
[PMID: 27098300]
[31]
Li F, Wu Y, Li X. Test-retest reliability and inter-rater reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in hemiplegic patients with stroke. Eur J Phys Rehabil Med 2014; 50(1): 9-15.
[PMID: 24309501]
[32]
Creamer M, Cloud G, Kossmehl P, et al. Effect of intrathecal baclofen on pain and quality of life in poststroke spasticity. Stroke 2018; 49(9): 2129-37.
[http://dx.doi.org/10.1161/STROKEAHA.118.022255] [PMID: 30354975]
[33]
Fang CY, Tsai JL, Li GS, Lien ASY, Chang YJ. Effects of robot-assisted gait training in individuals with spinal cord injury: A meta-analysis. BioMed Res Int 2020; 2020: 1-13.
[http://dx.doi.org/10.1155/2020/2102785] [PMID: 32280681]
[34]
Xie HM, Guo TT, Sun X, et al. Effectiveness of botulinum toxin A in treatment of hemiplegic shoulder pain: A systematic review and meta-analysis. Arch Phys Med Rehabil 2021; 102(9): 1775-87.
[http://dx.doi.org/10.1016/j.apmr.2020.12.010] [PMID: 33454279]
[35]
Field B, Scheinberg A, Cruickshank A. Health care services for adults with cerebral palsy. Aust Fam Physician 2010; 39(3): 165-7.
[PMID: 20369122]
[36]
Dressler D, Berweck S, Chatzikalfas A, et al. Intrathecal baclofen therapy in germany: Proceedings of the IAB—interdisciplinary working group for movement disorders consensus meeting. J Neural Transm 2015; 122(11): 1573-9.
[http://dx.doi.org/10.1007/s00702-015-1425-1] [PMID: 26179478]
[37]
Biering-Soerensen B, Stevenson V, Bensmail D, et al. European expert consensus on improving patient selection for the manage-ment of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. J Rehabil Med 2022; 54: jrm00241.
[http://dx.doi.org/10.2340/16501977-2877]
[38]
Saulino M, Ivanhoe CB, McGuire JR, Ridley B, Shilt JS, Boster AL. Best practices for intrathecal baclofen therapy: Patient selection. Neuromodulation 2016; 19(6): 607-15.
[http://dx.doi.org/10.1111/ner.12447] [PMID: 27434197]
[39]
Rizk T. Botulinum Toxin-A in Ped Spasticity. LAP 2014.
[40]
Lin Y, Wang G, Wang B. Rehabilitation treatment of spastic cerebral palsy with radial extracorporeal shock wave therapy and rehabilitation therapy. Medicine 2018; 97(51): e13828.
[http://dx.doi.org/10.1097/MD.0000000000013828] [PMID: 30572548]
[41]
Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet 2004; 363(9421): 1619-31.
[http://dx.doi.org/10.1016/S0140-6736(04)16207-7] [PMID: 15145637]
[42]
Goldstein EM. Spasticity management: An overview. J Child Neurol 2001; 16(1): 16-23.
[http://dx.doi.org/10.1177/088307380101600104] [PMID: 11225951]
[43]
Marty GR, Dias LS, Gaebler-Spira D. Selective posterior rhizotomy and soft-tissue procedures for the treatment of cerebral diplegia. J Bone Joint Surg Am 1995; 77(5): 713-8.
[http://dx.doi.org/10.2106/00004623-199505000-00007] [PMID: 7744896]
[44]
Spittle AJ, Morgan C, Olsen JE, Novak I, Cheong JLY. Early diagnosis and treatment of cerebral palsy in children with a history of preterm birth. Clin Perinatol 2018; 45(3): 409-20.
[http://dx.doi.org/10.1016/j.clp.2018.05.011] [PMID: 30144846]
[45]
Boyaci A, Tutoglu A, Boyaci N, et al. Changes in spastic muscle stiffness after botulinum toxin A injections as part of rehabilitation therapy in patients with spastic cerebral palsy. NeuroRehabilitation 2014; 35(1): 123-9.
[http://dx.doi.org/10.3233/NRE-141107] [PMID: 24990017]
[46]
Aşkın A, Kalaycı ÖT, Bayram KB, et al. Strain sonoelastographic evaluation of biceps muscle intrinsic stiffness after botulinum toxin- A injection. Top Stroke Rehabil 2017; 24(1): 12-7.
[http://dx.doi.org/10.1080/10749357.2016.1183865] [PMID: 27211845]
[47]
Mckinnon CT, Meehan EM, Harvey AR, Antolovich GC, Morgan PE. Prevalence and characteristics of pain in children and young adults with cerebral palsy: A systematic review. Dev Med Child Neurol 2019; 61(3): 305-14.
[http://dx.doi.org/10.1111/dmcn.14111] [PMID: 30508221]
[48]
Rizk T. Cerebral palsy-challenges for the future. In: Management of Spasticity & Cerebral Palsy. Intech 2014.
[49]
Massaro M, Pastore S, Ventura A, Barbi E. Pain in cognitively impaired children: A focus for general pediatricians. Eur J Pediatr 2013; 172(1): 9-14.
[http://dx.doi.org/10.1007/s00431-012-1720-x] [PMID: 22426858]
[50]
Penner M, Xie WY, Binepal N, Switzer L, Fehlings D. Characteristics of pain in children and youth with cerebral palsy. Pediatrics 2013; 132(2): e407-13.
[http://dx.doi.org/10.1542/peds.2013-0224] [PMID: 23858420]
[51]
Peck J, Urits I, Kassem H, et al. Interventional approaches to pain and spasticity related to cerebral palsy. Psychopharmacol Bull 2020; 50(4(S1)): 108-20.
[PMID: 33633421]
[52]
Smania N, Picelli A, Munari D, et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med 2010; 46(3): 423-38.
[PMID: 20927008]
[53]
Ianieri G, Saggini R, Marvulli R, et al. Botulinum toxin in cerebral child palsy. Int J Immunopathol Pharmacol 2009; 22(3_suppl): 9-11.
[http://dx.doi.org/10.1177/03946320090220S302] [PMID: 19887036]
[54]
FDA. Ongoing safety review of botox, botox cosmetic and myobloc (news release). 2008. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116857.htm (Accessed: 2011 Jun 24)
[55]
Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006; 21(3): 189-93.
[http://dx.doi.org/10.2310/7010.2006.00041] [PMID: 16901418]
[56]
Albavera-Hernández C, Rodríguez JM, Idrovo AJ. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: A systematic review of randomized clinical trials. Clin Rehabil 2009; 23(5): 394-407.
[http://dx.doi.org/10.1177/0269215508099860] [PMID: 19389744]
[57]
Marisa M, Riccardo M, Giacomo F, et al. Pain and Muscles Properties Modifications After Botulinum Toxin Type A (BTX-A) and Radial Extracorporeal Shock Wave (rESWT) Combined Treatment. Endocr Metab Immune Disord Drug Targets 2019; 19(8): 1127-33.
[http://dx.doi.org/10.2174/1871530319666190306101322] [PMID: 30843498]
[58]
Shaikh A, Phadke CP, Ismail F, Boulias C. Relationship between botulinum toxin, spasticity and pain: A survey of patient perception. Can J Neurol Sci 2016; 43(2): 311-5.
[http://dx.doi.org/10.1017/cjn.2015.321] [PMID: 26691344]
[59]
Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69(2): 217-21.
[http://dx.doi.org/10.1136/jnnp.69.2.217] [PMID: 10896696]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy